Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMGEN INCAMGN · Entity 2832 | Director | April 25, 2014 | April 29, 2014 |
| Amesite Inc.NONE · Entity 149985 | Director | March 31, 2020 | April 06, 2020 |
| Amesite Inc.AMST · Entity 8151 | Director | September 30, 2026 | October 03, 2026 |
| Elicio Therapeutics, Inc.ANGN · Entity 299 | Director | June 09, 2022 | June 13, 2022 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | Director | April 17, 2017 | April 19, 2017 |
| GALECTIN THERAPEUTICS INCGALT · Entity 5577 | Director | January 16, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMGEN INC
Report date April 25, 2014 · Filed April 29, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,547 |
Reported balance
After 2014-04-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2014-04-25 · Grant · Acquired 1,795 · Balance 180,547 F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2: These shares include 232 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule.
F2: These shares include 232 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.
Amesite Inc.
Report date March 31, 2020 · Filed April 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2030-03-31 | Direct | 50,000 |
Reported balance
After 2020-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-03-31 · Grant · Acquired 50,000 · Balance 50,000 F1: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2030-03-31 | Direct | 10,000 |
Reported balance
After 2020-03-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-31 · Grant · Acquired 10,000 · Balance 10,000 F2: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter.
F2: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter.
Amesite Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | IndirectBy Gilbert S. Omenn Revocable Trust | 95,927 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 12,121 · Balance 95,927 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AMST common stock and/or the cash equivalent of such share. F2: The reported securities were issued as "deferred stock units" in lieu of cash compensation earned for services as a director, and the number of deferred stock units received was calculated based on the closing share price on the last day of the quarter. The deferred stock units or cash equivalent will be issued to the reporting person upon completion of service as a member of the board of directors or, if earlier, a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of AMST common stock and/or the cash equivalent of such share.
F2: The reported securities were issued as "deferred stock units" in lieu of cash compensation earned for services as a director, and the number of deferred stock units received was calculated based on the closing share price on the last day of the quarter. The deferred stock units or cash equivalent will be issued to the reporting person upon completion of service as a member of the board of directors or, if earlier, a change in control.
Elicio Therapeutics, Inc.
Report date June 09, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.73 · Expires 2032-06-09 | Direct | 15,000 |
Reported balance
After 2022-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-09 · Grant · Acquired 15,000 · Balance 15,000 F1: 1.To vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1.To vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date.
Esperion Therapeutics, Inc.
Report date April 17, 2017 · Filed April 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2027-04-17 | Direct | 14,000 |
Reported balance
After 2017-04-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-17 · Grant · Acquired 14,000 · Balance 14,000 F1: The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017.
GALECTIN THERAPEUTICS INC
Report date January 16, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-01-16 | Direct | 60,000 |
Reported balance
After 2026-01-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-16 · Grant · Acquired 60,000 · Balance 60,000 F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. F2: The options vest 100% on December 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2: The options vest 100% on December 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2021 Filed Feb 12, 2021 00:23 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | ConversionCommon Stock | 23,483 | $11.57 | $271,698.31 |
DisclosureSEC source: 0001567619-21-003191 · doc1.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 42,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: Gilbert S. Omenn Revocable Trust. Read SEC document |
| September 29, 2020 Filed Sep 29, 2020 23:22 UTC | Amesite Inc. AMST · Entity 8151 | PurchaseCommon Stock | 20,000 | $5.00 | $100,000.00 |
DisclosureSEC source: 0001213900-20-028985 · ownership.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Gilbert S. Omenn Revocable Trust Disclosed balance after: 61,666 Read SEC document |
| March 31, 2020 Filed Apr 6, 2020 19:13 UTC | Amesite Inc. NONE · Entity 149985 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001213900-20-008705 · ownership.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-03-31 F2 · derivative.exercise_date: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter. Read SEC document |
| March 31, 2020 Filed Apr 6, 2020 19:13 UTC | Amesite Inc. NONE · Entity 149985 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001213900-20-008705 · ownership.xml · derivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-03-31 F1 · derivative.exercise_date: 50% of the options shall vest on March 31, 2021 and the remaining 50% of the options shall vest and become exercisable in twelve (12) successive equal monthly installments thereafter. Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 22:55 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-20-001112 · doc4.xml · derivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-01-09 F1 · security: The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options vest 100% on December 31, 2020. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:29 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock Purchase Warrant (right to buy) · Derivative | 61,929 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001179022-19-000034 · edgar.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,929 Underlying: Common stock · 4,644 shares Expires 2026-05-31 F1 · shares: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. F1 · balance_after: Each warrant is exerciseable for 0.075 shares of Common Stock of the Company. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 21:29 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | PurchaseCommon Stock | 18,578 | $4.28 | $79,513.84 |
DisclosureSEC source: 0001179022-19-000034 · edgar.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,769 Read SEC document |
| January 16, 2019 Filed Jan 18, 2019 22:18 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 35,000 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0001179022-19-000014 · edgar.xml · derivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common stock · 35,000 shares Expires 2029-01-16 F1 · derivative.exercise_date: The options vest 100% on January 16, 2020. Read SEC document |
| September 10, 2018 Filed Sep 11, 2018 20:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 8,370 | $6.00 | $50,220.00 |
DisclosureSEC source: 0001179022-18-000071 · edgar.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,191 Read SEC document |
| September 07, 2018 Filed Sep 11, 2018 20:06 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | SaleCommon Stock | 11,000 | $6.03 | $66,365.20 |
DisclosureSEC source: 0001179022-18-000071 · edgar.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,561 F1 · price: The shares were sold in multiple transactions at prices ranging from $6.0131 to $6.05. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 21:11 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 62,250 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001179022-17-000076 · edgar.xml · derivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,250 Underlying: Common stock · 62,250 shares Expires 2027-12-14 F1 · derivative.exercise_date: The options vest 100% on December 14, 2018. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 10:50 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $38.96 | $0.00 |
DisclosureSEC source: 0001179110-17-006065 · edgar.xml · derivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-04-17 F1 · derivative.exercise_date: The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017. Read SEC document |
| March 21, 2017 Filed Mar 22, 2017 12:02 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 1,000 | $42.26 | $42,260.00 |
DisclosureSEC source: 0001104659-17-018473 · a4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Gilbert S. Omenn Revocable Trust Disclosed balance after: 1,000 Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 21:26 UTC | GALECTIN THERAPEUTICS INC GALT · Entity 5577 | GrantStock option (right to buy) · Derivative | 41,500 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001179022-16-000132 · edgar.xml · derivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,500 Underlying: Common stock · 41,500 shares Expires 2026-12-15 F1 · derivative.exercise_date: The options vest 100% on the date of Galectin Therapeutics, Inc.'s 2017 Annual Stockholders Meeting. Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:20 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-015495 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,547 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 232 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 22:02 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-014805 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,669 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the Director Program) and vested immediately. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 149 Dividend Equivalents (DEs) granted pursuant to the Director Program and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 26, 2012 Filed Nov 27, 2012 01:45 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $62.55 | $0.00 |
DisclosureSEC source: 0001127602-12-032078 · form4.xml · derivative · entry 7 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2014-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2012 Filed Nov 27, 2012 01:45 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $74.89 | $0.00 |
DisclosureSEC source: 0001127602-12-032078 · form4.xml · derivative · entry 6 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2013-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2012 Filed Nov 27, 2012 01:45 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $50.78 | $0.00 |
DisclosureSEC source: 0001127602-12-032078 · form4.xml · derivative · entry 5 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2013-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2012 Filed Nov 27, 2012 01:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 26,000 | $87.11 | $2,264,984.80 |
DisclosureSEC source: 0001127602-12-032078 · form4.xml · nonDerivative · entry 4 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,783 F1 · price: The price reported is an average price. The prices ranged from $87.095 to $87.13 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include 108 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| November 26, 2012 Filed Nov 27, 2012 01:45 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,000 | $62.55 | $312,750.00 |
DisclosureSEC source: 0001127602-12-032078 · form4.xml · nonDerivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2012 Filed Nov 27, 2012 01:45 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,000 | $74.89 | $374,450.00 |
DisclosureSEC source: 0001127602-12-032078 · form4.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2012 Filed Nov 27, 2012 01:45 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 16,000 | $50.78 | $812,480.00 |
DisclosureSEC source: 0001127602-12-032078 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2012 Filed Oct 26, 2012 23:37 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 8,572 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-029163 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,783 F1 · balance_after: These shares include 108 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the director's unvested, and vested but deferred, Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2012 Filed May 1, 2012 23:55 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $71.64 Strike: $71.64 | $358,200.00 |
DisclosureSEC source: 0001127602-12-015229 · form4.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2022-04-27 Read SEC document |
| April 27, 2012 Filed May 1, 2012 23:55 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,395 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-015229 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,313 F1 · shares: The Restricted Stock Units ("RSUs") were granted pursuant to the Amgen Inc. 2009 Director Incentive Program, as amended, under the Amgen Inc. 2009 Equity Incentive Plan (the "Director Program") and vested immediately because the director has three years or more of prior continuous service as a director. Vested RSUs are paid in shares of the Company's common stock on a one-to-one basis. Vested RSUs may be deferred by the director, in which case, payment will occur according to the elected deferral schedule. F2 · balance_after: These shares include 66 Dividend Equivalents ("DEs") granted pursuant to the Director Program. The acquisition of DEs had previously been reported in Table II of the director's Form 4 filings prior to the Company implementing a qualifying dividend reinvestment plan in 2012. DEs are credited on the director's unvested, and vested but deferred, RSUs and are paid out in shares of the Company's common stock on a one-to-one basis along with a cash payment for any remaining fractional share amount. Read SEC document |
| February 29, 2012 Filed Feb 29, 2012 23:28 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $58.61 | $0.00 |
DisclosureSEC source: 0001127602-12-008750 · form4.xml · derivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2012-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Feb 29, 2012 23:28 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 4,301 | $68.15 | $293,113.15 |
DisclosureSEC source: 0001127602-12-008750 · form4.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,852 Read SEC document |
| February 29, 2012 Filed Feb 29, 2012 23:28 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 5,000 | $58.61 | $293,050.00 |
DisclosureSEC source: 0001127602-12-008750 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2011 Filed Dec 22, 2011 21:43 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $56.30 | $0.00 |
DisclosureSEC source: 0001127602-11-033102 · form4.xml · derivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2012-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 22, 2011 Filed Dec 22, 2011 21:43 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 14,267 | $63.14 | $900,818.38 |
DisclosureSEC source: 0001127602-11-033102 · form4.xml · nonDerivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,153 Read SEC document |
| December 22, 2011 Filed Dec 22, 2011 21:43 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 16,000 | $56.30 | $900,800.00 |
DisclosureSEC source: 0001127602-11-033102 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2011 Filed Dec 13, 2011 00:02 UTC | AMGEN INC AMGN · Entity 2832 | GrantDividend Equivalent · Derivative | 20.984 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-031948 · form4.xml · derivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43.0306 Underlying: Common Stock · 20.984 shares Expires not disclosed F1 · derivative.exercise_price: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.exercise_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.expiration_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. Read SEC document |
| September 08, 2011 Filed Sep 12, 2011 21:33 UTC | AMGEN INC AMGN · Entity 2832 | GrantDividend Equivalent · Derivative | 22.0466 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-025063 · form4.xml · derivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22.0466 Underlying: Common Stock · 22.0466 shares Expires not disclosed F1 · derivative.exercise_price: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.exercise_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. F1 · derivative.expiration_date: The Dividend Equivalents were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. The Dividend Equivalents are credited and deemed reinvested in the director's account in lieu of a cash dividend payment on the director's vested but deferred Restricted Stock Units. Dividend Equivalents will be paid in whole shares of the Company's common stock on a one-to-one basis on the director's elected deferral date, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 00:17 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $54.69 Strike: $54.69 | $273,450.00 |
DisclosureSEC source: 0001127602-11-013860 · form4.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2021-04-25 Read SEC document |
| April 25, 2011 Filed Apr 28, 2011 00:17 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-11-013860 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,420 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Director Equity Incentive Program under the Amgen Inc. 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| April 26, 2010 Filed Apr 28, 2010 22:27 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $58.43 Strike: $58.43 | $292,150.00 |
DisclosureSEC source: 0001127602-10-012357 · form4.xml · derivative · entry 2 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2020-04-26 Read SEC document |
| April 26, 2010 Filed Apr 28, 2010 22:27 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,711 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-10-012357 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,592 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's 2009 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director has had less than three years of prior continuous service as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| December 30, 2009 Filed Jan 6, 2010 01:08 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 13,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-10-000725 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,881 Read SEC document |
| September 28, 2009 Filed Sep 30, 2009 17:32 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 1,191 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-09-019620 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,831 Read SEC document |
| April 28, 2009 Filed Apr 30, 2009 17:28 UTC | AMGEN INC AMGN · Entity 2832 | GrantNqso (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $50.44 | $0.00 |
DisclosureSEC source: 0001127602-09-010051 · form4.xml · derivative · entry 3 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2016-04-28 Read SEC document |
| April 28, 2009 Filed Apr 30, 2009 17:28 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 1,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-09-010051 · form4.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,982 F1 · security: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. Director Equity Incentive Program under the Company's Amended and Restated 1991 Equity Incentive Plan. RSUs vest (a) immediately for directors who have three years or more of prior continuous service as a director, or (b) one year from the grant date if the director had had less than three years of prior continuous services as a director. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis unless payment is otherwise deferred by the director. Read SEC document |
| December 29, 2008 Filed Jan 14, 2009 17:29 UTC | AMGEN INC AMGN · Entity 2832 | GiftCommon Stock | 1,800 | $56.87 | $102,366.00 |
DisclosureSEC source: 0001127602-09-001142 · form5.xml · nonDerivative · entry 1 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,040 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $28.97 | $0.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · derivative · entry 20 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2009-01-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 400 | $58.06 | $23,224.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 19 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,840 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 1,100 | $58.05 | $63,855.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 18 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,240 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 500 | $58.19 | $29,095.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 17 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,340 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $57.87 | $5,787.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 16 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,840 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 300 | $58.11 | $17,433.00 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 15 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,940 Read SEC document |
| December 08, 2008 Filed Dec 9, 2008 21:45 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 100 | $58.09 | $5,808.50 |
DisclosureSEC source: 0001127602-08-010813 · form4.xml · nonDerivative · entry 14 OMENN GILBERT S · CIK 0001184227 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,240 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.